The beat-and-raise quarter with accelerated buybacks is a clear positive. Monitor the Q4 print for continued execution on OneOncology integration and margin expansion in U.S. Healthcare Solutions. The accelerated $1B buyback signals management confidence in cash flow generation.
Price Chart
Executive Summary
Cencora reported fiscal Q3 2026 revenue of $84.8B (+5.1% YoY) and adjusted diluted EPS of $4.48, beating consensus estimates of $4.35 by 3.0%. The company raised its full-year adjusted EPS guidance to $17.75-$17.95 and repurchased $1B in shares during the quarter, signaling strong operational momentum and capital return to shareholders.
Key Financial Metrics
Key Facts
- Revenue of $84.8B, up 5.1% YoY, beating $84.15B consensus
- Adjusted diluted EPS of $4.48, up 12.0% YoY, beating $4.35 consensus
- FY2026 adjusted EPS guidance raised to $17.75-$17.95 from $17.70-$17.90
- Repurchased $1B in shares during Q3, accelerating the prior $1B target from end of calendar 2026
- U.S. Healthcare Solutions segment operating income up 15.9% YoY, driven by OneOncology acquisition
- International Healthcare Solutions segment operating income up 20.8% YoY
- GAAP diluted EPS of $3.94, up 11.9% YoY
- Quarterly dividend maintained at $0.60 per share
Financial Impact
Revenue beat consensus by ~$650M; adjusted EPS beat by $0.13 (3.0%); FY guidance raised by $0.05 at midpoint
Risk Factors
- Higher interest expense ($140.7M, +72% YoY) from debt financing of OneOncology
- GLP-1 mix shift continues to pressure gross margins
- Opioid litigation liability remains at $3.8B on balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140859-26-000032 |
| Document: abc-20260805.htm | 0001140859-26-000032 |
| Document: 0001140859-26-000032-index-headers.html | 0001140859-26-000032 |
| Document: 0001140859-26-000032-index.html | 0001140859-26-000032 |
| Document: 0001140859-26-000032.txt | 0001140859-26-000032 |
| 8-K Data (Synthetic) | 0001140859-26-000032 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $318.04 $308.78 | ▼ −2.91% | ▼ −2.63% | $309.78 (−2.60%) |
Aug 5, 2026 8w ago | 8-K | $317.22 $336.36 | ▲ +6.03% | ▲ +6.64% | $309.78 (−2.35%) |
Aug 5, 2026 8w ago | 8-K | $317.22 $336.36 | ▲ +6.03% | ▲ +6.64% | $309.78 (−2.35%) |
Jun 15, 2026 15w ago | 8-K | $281.46 $302.28 | ▲ +7.40% | ▲ +7.20% | $309.78 (+10.06%) |
May 29, 2026 17w ago | 8-K | $264.69 $282.98 | ▲ +6.91% | ▲ +8.21% | $309.78 (+17.04%) |
May 6, 2026 21w ago | 8-K | $252.74 $263.64 | ▲ +4.31% | ▲ +1.53% | $309.78 (+22.57%) |
Feb 28, 2026 30w ago | Institutional Cluster | $372.65 $309.93 | ▼ −16.83% | ▼ −8.89% | $309.78 (−16.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access